<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article125</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/NEAT-HFpEF" style="display:block; margin-bottom:10px;">NEAT-HFpEF Original</a></li>
<h2><strong>NEAT-HFpEF</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>
<br/>
<br/>
### Clinical Question<br/>
Does isosorbide mononitrate improve daily activity in patients with heart failure and a preserved ejection fraction?<br/>
<br/>
### Bottom Line<br/>
Isosorbide mononitrate did not improve the daily activity level, submaximal exercise capacity, quality-of-life scores, or NT-proBNP levels, and actually decreased daily activity levels in patients with heart failure and a preserved ejection fraction.<br/>
<br/>
### Major Points<br/><br/>
<br/>
### Guidelines<br/><br/>
<br/>
### Design<br/>
Multicenter, double-blind, crossover, randomized, placebo-controlled trial.<br/>
<br/>
- **N** = 110 patients with HFpEF<br/>
- **Interventions**: Isosorbide mononitrate (30 mg to 120 mg once daily) vs placebo<br/>
- **Setting**: 20 US sites<br/>
- **Enrollment**: April 7, 2014, to October 30, 2014<br/>
- **Mean follow-up**: 6 weeks per treatment phase<br/>
- **Analysis**: Intention-to-treat<br/>
- **Primary outcome**: Average daily activity level assessed by accelerometry during 120-mg phase<br/>
<br/>
### Population<br/>
<br/>
#### Inclusion Criteria<br/>
- Heart failure diagnosis<br/>
- Age ≥50 years<br/>
- Ejection fraction ≥50%<br/>
- Objective evidence of heart failure (hospitalization for heart failure, elevated left ventricular end diastolic or pulmonary capillary wedge pressure, elevated NT-proBNP or BNP levels, or echocardiographic evidence of diastolic dysfunction)<br/>
- Heart failure symptoms as the primary reason for limited activity<br/>
<br/>
#### Exclusion Criteria<br/>
- Systolic blood pressure &lt;110 mm Hg or &gt;180 mm Hg<br/>
- Adverse reaction or current use of long-term nitrate or phosphodiesterase type 5 inhibitor therapy<br/>
<br/>
#### Baseline Characteristics<br/>
- Mean age 69 years, 57% female<br/>
- Majority were white and obese<br/>
- Majority had controlled blood pressure and multiple coexisting illnesses<br/>
- Most patients were on multiple cardiovascular medications<br/>
- Mean ejection fraction was 63%<br/>
<br/>
### Interventions<br/>
- Isosorbide mononitrate - dose-escalation regimen 30 mg to 120 mg once daily for 6 weeks.<br/>
- Placebo for 6 weeks.<br/>
- Crossover design, so patients received both treatments sequentially with washout period.<br/>
<br/>
### Outcomes<br/>
<br/>
#### Primary Outcome<br/>
- No significant improvement in average daily activity levels during the 120-mg phase of isosorbide mononitrate vs placebo.<br/>
<br/>
#### Secondary Outcomes<br/>
- Decrease in hours of activity per day with isosorbide mononitrate.<br/>
- No significant difference in 6-minute walk distance, quality-of-life scores, or NT-proBNP levels compared to placebo.<br/>
<br/>
### Criticisms<br/>
- Rapid dose escalation of isosorbide mononitrate may have limited assessment of tolerability.<br/>
- Absence of longer-term outcomes assessment.<br/>
- No improvement in exercise tolerance and reduction of daily activity levels limits applicability.<br/>
<br/>
### Funding<br/>
National Heart, Lung, and Blood Institute (NHLBI) grants.<br/>
<br/>
### Further Reading<br/>
Full article and supplementary materials available at NEJM.org.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
